Commercial/Healthcare Exchange PA Criteria

Effective: October 20, 2020

Prior Authorization: Cystadrops-Cystaran Ophthalmic Solution

Products Affected: Cystadrops 0.37% and Cystaran 0.44% ophthalmic solution

Medication Description: Cysteamine, an aminothiol, decreases the amount of cystine in the lysosomes of patients with cystinosis. Exogenous cysteamine enters the cell and converts cystine to cysteine and a cysteine-cysteamine complex. Both cysteine and the cysteine-cysteamine complex are more readily transported out of the lysosome than cystine, resulting in a long-term depletion of lysosomal cystine.

Covered Uses: Treatment of corneal cystine crystal accumulation in patients with cystinosis.

Exclusion Criteria: N/A

Required Medical Information: Diagnosis

Age Restrictions: N/A

Prescriber Restrictions: N/A

Coverage Duration: 3 years

Other Criteria:

Initial:

A. Patient has a diagnosis of cystinosis; **AND**
B. Patient has corneal cystine crystal deposits

Continuation:

A. Documentation showing improved or disease stabilization.

References:

1. Cystadrops 0.37% [prescribing information]. Lebanon, NJ: Recordati Rare Diseases Inc; September 2020. Accessed December 17, 2020.
2. Cystaran 0.44% [prescribing information]. Gaithersburg, MD: Leadiant Biosciences, Inc.; November 2020. Accessed December 17, 2020.

Policy Revision History:

Rev #	Type of Change	Summary of Change	Sections Affected	Date

1	New Policy	New Policy	All	10/2020
2	Update	Added Cystaran to products affected Changed policy name to Cystadrops-Cystaran Added continuation criteria	All	1/1/2021